Press Releases

 
Press Releases
  Date Title and Summary View
Jun 19, 2003
PITTSBURGH, Jun 19, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Mirtazapine Tablets in 15 mg, 30 mg and 45 mg strengths. Mirtazapine is the generic version of Organon Inc.'s, Remeron...
Jun 19, 2003
PITTSBURGH--(BUSINESS WIRE)--June 19, 2003--Mylan Laboratories' (NYSE:MYL) brand subsidiary, Bertek Pharmaceuticals received an Untitled Letter from the United States Food and Drug Administration (FDA) regarding a certain specific reference on its Amnesteem® website. Having been made aware of th...
Jun 16, 2003
PITTSBURGH--(BUSINESS WIRE)--June 16, 2003--Mylan Laboratories Inc. (NYSE:MYL) announced today that the regular quarterly cash dividend of $0.0333 per share will be paid on July 15, 2003, to shareholders of record on June 30, 2003. Mylan Laboratories Inc. is a leading pharmaceutical company that develops, manufactures and markets gener...
Jun 2, 2003
PITTSBURGH, Jun 2, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Omeprazole Delayed-release Capsules, 10 mg and 20 mg strengths and tentative approval for the 40 mg strength. O...
May 8, 2003
PITTSBURGH--(BUSINESS WIRE)--May 8, 2003--Mylan Laboratories Inc. (NYSE: MYL) Financial Highlights -- Record diluted earnings per share of $1.45 for fiscal 2003 and $.40 for the fourth quarter, compared to $1.36 and $.35, respectively, in the prior year. -- Net revenues increased by 15% to a record $1.27 b
Apr 28, 2003
CANONSBURG, Pa., Apr 28, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that it will release its fourth quarter and fiscal 2003 financial results before the market opens on Thursday, May 8, 2003. Mylan management will host a conference call and live Webcast at 10:00 AM EDT to discuss the financial resul...
Apr 11, 2003
PITTSBURGH, Pa.--(BUSINESS WIRE)--April 11, 2003--Mylan Laboratories Inc. (NYSE:MYL) announced today that it has agreed to a tentative settlement under which it will receive $12.5 million from Aventis Pharmaceuticals, Inc. The Company also announced that it will receive an additional $10 million from its co-defendants in the lorazep...
Apr 10, 2003
PITTSBURGH, Pa.--(BUSINESS WIRE)--April 10, 2003--Mylan Laboratories Inc. (NYSE: MYL) a leading developer, manufacturer and marketer of generic and proprietary pharmaceuticals announced today the relocation of its Corporate Headquarters to a new state-of-the-art office complex in Canonsburg, Pennsylvania. The new offices, within the...
Apr 2, 2003
PITTSBURGH--(BUSINESS WIRE)--April 2, 2003--Mylan Laboratories Inc. (NYSE: MYL) announced today that it received confirmation from the FDA in February, 2003 that the Company's Modafinil (Provigil®) ANDA has been accepted for filing. The FDA accepted Mylan's application which contains a Paragraph ...
Apr 2, 2003
Apr 02, 2003 (BUSINESS WIRE) -- In BW 5131 (PA-MYLAN-LABORATORIES) Mylan Announces Filing of Modafinil ANDA, in the second graf, first sentence, read it xxx December 24, 2002 (sted xxx December 24, 2003). The full corrected sentence reads: The FDA accepted Mylan's application which contains a Paragraph IV certification...
Page: FirstPrevious ...
108
... NextLast
= add release to Briefcase